ENGLAND

We Asked Americans, What’s Your Favorite Nutritious Way to Eat Potatoes?

Retrieved on: 
Wednesday, May 17, 2023
Retail, Fitness & Nutrition, Health, Food, Beverage, Nutrition, Magnesium, Dietitian, DV, Nutrient, Vitamin C, Multimedia, Calcium, Journal, ENGLAND, Iron, Research, Potassium, Journal of the Academy of Nutrition and Dietetics, Potato, Food preservation, Baking, Flour

We can all agree that potatoes are America’s favorite vegetable, but a recent Potatoes USA survey investigated different regions’ preferred, nutritious ways to eat the mighty spud.

Key Points: 
  • We can all agree that potatoes are America’s favorite vegetable, but a recent Potatoes USA survey investigated different regions’ preferred, nutritious ways to eat the mighty spud.
  • View the full release here: https://www.businesswire.com/news/home/20230517005485/en/
    See how your region stacks up in nutritious potato preferences.
  • “I also know there are as many favorite potato dishes as there are Americans, and we loved seeing how people put the versatile potato to work in nutritious ways.”
    When Americans were asked their favorite nutritious way to eat potatoes, baked came in on top (41%), followed by mashed potatoes (17%).
  • “Potatoes are nutritious, delicious and affordable – and that’s something we can all agree on,” Johnson added.

New England Biolabs® Introduces NEB Lyophilization Sciences™, Ltd.

Retrieved on: 
Thursday, December 1, 2022
Inc., FGL, RNA, Multimedia, Enzyme, PCR, Business operations, ENGLAND, OEM, Molecular biology, Therapy, NEB, Gene expression, Synthetic biology, Vaccine, Acquisition, Oil, Fine chemical, Medicine, New England Biolabs

IPSWICH, Mass., Dec. 1, 2022 /PRNewswire/ -- New England Biolabs (NEB®), a leading supplier of life science reagents, introduces New England Biolabs Lyophilization Sciences (NEB Lyo Sciences™) – a wholly owned subsidiary of NEB with expertise in the design, development and manufacturing of innovative solutions for ambient stored products.

Key Points: 
  • IPSWICH, Mass., Dec. 1, 2022 /PRNewswire/ -- New England Biolabs (NEB), a leading supplier of life science reagents, introduces New England Biolabs Lyophilization Sciences (NEB Lyo Sciences) a wholly owned subsidiary of NEB with expertise in the design, development and manufacturing of innovative solutions for ambient stored products.
  • In May 2021, NEB acquired Fluorogenics Limited (FGL), facilitating the combination of NEB's expertise in enzymology with FGL's extensive understanding of the lyophilization process.
  • NEB will continue to incorporate the capabilities of NEB Lyo Sciences into its existing OEM and Customized Solutions business, expanding the services that it offers.
  • NEW ENGLAND BIOLABSand NEBare registered trademarks of New England Biolabs, Inc.
    NEW ENGLAND BIOLABS LYOPHILIZATION SCIENCES, NEB LYO SCIENCES and LYOPRIME are trademarks of New England Biolabs, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/new-england-biolabs-introduces-...

New England Biolabs® Introduces Faustovirus Capping Enzyme, a Novel Enzymatic mRNA Capping Solution for mRNA Manufacturing

Retrieved on: 
Tuesday, August 9, 2022
Multimedia, Synthetic biology, RNA transfection, Industry, NEW, Gene expression, ENGLAND, Infection, Molecular biology, ISO 9001, Research, Enzyme, Faustovirus, Compliance, Hazardous waste, View, Therapy, Vaccine, GMP, RNA, NEB, Active ingredient, ISO, PCR, API, Efficiency, Temperature, FCE, VCE, Fine chemical, New England Biolabs

IPSWICH, Mass., Aug. 9, 2022 /PRNewswire/ -- Today, New England Biolabs (NEB®) announces the release of the Faustovirus Capping Enzyme (FCE), an mRNA capping solution that combines high activity and a broad temperature range to support mRNA therapeutic manufacturing needs.

Key Points: 
  • New enzyme improves capping efficiency and scalability for mRNA manufacturing workflows, including vaccine generation
    IPSWICH, Mass., Aug. 9, 2022 /PRNewswire/ -- Today, New England Biolabs (NEB) announces the release of the Faustovirus Capping Enzyme (FCE), an mRNA capping solution that combines high activity and a broad temperature range to support mRNA therapeutic manufacturing needs.
  • This new product offers a streamlined, scalable, and cost-effective solution for mRNA capping for both research and therapeutic applications."
  • "For large-scale mRNA production, I have always favored post-transcriptional enzymatic capping due to the significant advantages in terms of yield.
  • NEB and NEW ENGLAND BIOLABS are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/new-england-biolabs-introduces-...

The Boston Globe Names New England Biolabs® a Top Place to Work for 2021

Retrieved on: 
Tuesday, December 7, 2021
Environment, Twitter, PCR, Workplace, Workforce, Globe, The Boston Globe, View, News, Synthetic biology, CEO, Industry, NEB, Organization, Science, Molecular biology, Work, Multimedia, Boston, ENGLAND, RNA, Enzyme, NEW, Human, Gene expression, Happiness, Management

IPSWICH, Mass., Dec. 7, 2021 /PRNewswire/ -- New England Biolabs (NEB) has been named one of theTop Places toWorkin Massachusetts in the 14th annual employee-based survey project from The Boston Globe.

Key Points: 
  • IPSWICH, Mass., Dec. 7, 2021 /PRNewswire/ -- New England Biolabs (NEB) has been named one of theTop Places toWorkin Massachusetts in the 14th annual employee-based survey project from The Boston Globe.
  • TheTop Places to Work2021issue publishes online at globe.com/topplaces on the night of December 1st and inThe Boston Globe Magazineon December 5th.
  • The survey measures employee opinions about their company's direction, execution, connection, management, work, pay and benefits, and engagement.
  • NEW ENGLAND BIOLABSand NEBare registered trademarks of New England Biolabs, In
    View original content to download multimedia: https://www.prnewswire.com/news-releases/the-boston-globe-names-new-engl...

New England Biolabs® releases next generation HiScribe™ in vitro transcription kit, incorporating TriLink® Biotechnologies' CleanCap® technology for mRNA synthesis

Retrieved on: 
Monday, November 8, 2021
Compliance, Business, Industry, RNA transfection, CDMO, Acceleration, PCR, Melamaravakkadu, NASDAQ, CGMP, RNA, ENGLAND, ISO, NEW, COVID-19, Multimedia, Research, Gene expression, API, LLC, Test pilot, Organic acid, Active ingredient, Vaccine, Synthetic biology, Molecular biology, Cap 1, NEB, Enzyme, AG, ISO 9001, DNA, IVT

"The newHiScribeT7 mRNA Kit withCleanCapReagent AG combines NEB'sdeep expertise in enzymology withTriLink'snovelCleanCaptechnology, enabling the acceleration of research and development byallowingscientiststo easily generate high-quality mRNA and quickly screen many different molecules or designs."

Key Points: 
  • "The newHiScribeT7 mRNA Kit withCleanCapReagent AG combines NEB'sdeep expertise in enzymology withTriLink'snovelCleanCaptechnology, enabling the acceleration of research and development byallowingscientiststo easily generate high-quality mRNA and quickly screen many different molecules or designs."
  • "TriLink is proud to be included in the next generation of NEB in vitro transcription kits," said Brian Neel, Chief Operating Officer of TriLink Biotechnologies.
  • The HiScribe platform is a perfect complement to CleanCap technology."
  • TriLink's San Diego CA headquarters has grown to enable TriLink to meet the global demand for CleanCap reagent and supports several COVID-19 vaccine programs globally.